Science

First targeted therapy for Guillain-Barré syndrome nears approval by turning off rogue immune activity

New Scientist posted on X on Aug. 2 that a treatment turning off the part of the immune system that goes haywire in Guillain-Barré syndrome may be the first targeted therapy approved for the autoimmune condition. The post links to a New Scientist article about the potential approval. The treatment targets the rogue immune activity underlying the syndrome. No regulatory decision or timeline was disclosed in the post.
Sources
newscientist
Published by Tech & Business, a media brand covering technology and business. This story was sourced from newscientist and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Security Infrastructure
Security Infrastructure

Port of Los Angeles reports 120 million cyberattack attempts

The Port of Los Angeles foiled more than 120 million cyberattack attempts in August, according to Bloomberg. The U.S.'s busiest container port for global trade faces a persistent operational threat while navigating shifting tariff...

Bloomberg Technology
Security
Security

Cisco warns of actively exploited ISE authentication bypass

Cisco warned that CVE-2026-76460, a maximum-severity flaw in Identity Services Engine and ISE Passive Identity Connector, is being actively exploited. The reported API authentication-control weakness can let an unauthenticated rem...

The Hacker News
Capital Security
Capital Security

Comp AI raises $34 million Series A for compliance platform

Cybersecurity and compliance startup Comp AI has raised a $34 million Series A led by Roo Capital and Grand Ventures. The company says its platform uses AI agents to draft security policies, collect audit evidence and continuousl...

TechCrunch
Capital Robotics
Capital Robotics

Treble raises €15 million for acoustic AI simulation

Reykjavík-based Treble raised approximately €15 million in a Series A-2 round led by Paladin Capital Group, bringing its total funding to €36 million. Treble's cloud platform models sound in physical spaces to create synthetic aud...

EU-Startups
Science
Science

Phase-one mesothelioma study reports PRX3 inhibitor results

Researchers at the University of Vermont and collaborators reported phase-one results for RSO-021, a clinical formulation of thiostrepton, in relapsed mesothelioma. In 15 patients, the trial controlled disease progression in 67%;...

All Top News -- ScienceDaily
Robotics Science
Robotics Science

MIT demonstrates reconfigurable robotic optics lab

MIT researchers demonstrated a reconfigurable robotic optics lab that autonomously assembled and tuned a tabletop laser cavity. The seven-jointed arm picked, placed and adjusted optical components, completing 50 maneuvers within 3...

MIT News